TSX · XLY.TO
Auxly Cannabis Group Inc.
CA$3.67+CA$0.09 (+2.51%)
Auxly Cannabis Group Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.13% below the high.
Loading market information…
TSX · LOVE.TO · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Cannara Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cannara Biotech Inc.’s next earnings report is currently expected on Nov 23, 2026, with estimated earnings per share of CA$0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cannara Biotech Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| Jan 27, 2025 |
| CA$0.03 |
| CA$25.07M |
| Q4 2024 | Nov 25, 2024 | CA$0.06 | CA$23.04M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$3.67+CA$0.09 (+2.51%)
Auxly Cannabis Group Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.13% below the high.
CA$4.98+CA$0.02 (+0.4%)
Quipt Home Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.4% below the high.
CA$9.60+CA$0.57 (+6.31%)
Satellos Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.42% below the high.
CA$1.66-CA$0.02 (-1.19%)
Cardiol Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.61% below the high.
CA$16.83-CA$0.17 (-1.0%)
BioSyent Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.83% below the high.
$0.53+$0.01 (+2.8%)
Jushi Holdings Inc’s quoted price sits in the lower half of its reported 52-week range, 41.64% below the high.
CA$4.56+CA$0.00 (0.0%)
HLS Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.97% below the high.
$0.34+$0.00 (+0.02%)
Grown Rogue International Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.48% below the high.
